Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.
Keywords: CCR9; Crohn’s disease; IBD; Sulfonamide; Ulcerative colitis.
Copyright © 2015 Elsevier Ltd. All rights reserved.